Русский
Use of cytomedins in case of prostatic involvement in chronic prostatitis according to UPOINT classification
DOI: https://dx.doi.org/10.18565/urology.2019.3.31-35
D.V. Ergakov, A.G. Martov, D.E. Turin
Department of Urology and Andrology (Head – MD, prof. A.G. Martov) of A.I. Burnazyan SRC FMBC, FMBA of Russia, Moscow, Russia; GBUZ “City clinical hospital named after D.D. Pletnev of the Health Department c. Moscow” (Chief – Ph.D. I.A. Nazarova), Moscow, Russia
Background: chronic prostatitis is a common disease that significantly influence on the quality of life.
Aim: Our aim was to assess the prevalence of particular domains of UPOINT classification and determine the efficiency of prostate-selective cytomedins in complex therapy of chronic prostatitis with the predominance of organic component.
Materials and methods: a total of 96 patients aged from 24 to 48 years were treated in City clinical hospital named after D.D. Pletnev in 2017–2018 yy. with a previously diagnosed chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The mean duration of the disease was 18.0±6.2 months. The total NIH-CPSI score was 24±7.3 (pain score 9±4.9, urinary score 7±2,7, quality of life 8±2.3), Qmax was 16±4.2 ml/s, prostate volume – 34±12 cc. Leukocyturia in post-massage urine was found in 52 patients (54%). Positive urine culture after prostate massage or positive bacterial semen study were found in 22 patients (23%). Prostate-specific therapy consisted of 20 days of rectal suppositories Vitaprost-forte® followed by oral therapy by Vitaprost® tablet of the same duration.
Results: Follow-up examination of 72 patients (75%) was performed after 3 months of therapy. The total NIH-CSPI score decreased to 15.6±5.1 (pain score 6.3±3.8, urinary score 4.6±2.2, quality of life 4.7±2), Qmax was 16±3.8 ml/s and mean prostate volume was 24±6 cc. The normalization of laboratory parameters was achieved in all cases.
Conclusion: using the UPOINT classification allows to optimize the treatment of patients with chronic prostatitis. Use of prostate-specific cytomedins (Vitaprost®) is highly effective in case of prostatic involvement according to the UPOINT classification.
Aim: Our aim was to assess the prevalence of particular domains of UPOINT classification and determine the efficiency of prostate-selective cytomedins in complex therapy of chronic prostatitis with the predominance of organic component.
Materials and methods: a total of 96 patients aged from 24 to 48 years were treated in City clinical hospital named after D.D. Pletnev in 2017–2018 yy. with a previously diagnosed chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The mean duration of the disease was 18.0±6.2 months. The total NIH-CPSI score was 24±7.3 (pain score 9±4.9, urinary score 7±2,7, quality of life 8±2.3), Qmax was 16±4.2 ml/s, prostate volume – 34±12 cc. Leukocyturia in post-massage urine was found in 52 patients (54%). Positive urine culture after prostate massage or positive bacterial semen study were found in 22 patients (23%). Prostate-specific therapy consisted of 20 days of rectal suppositories Vitaprost-forte® followed by oral therapy by Vitaprost® tablet of the same duration.
Results: Follow-up examination of 72 patients (75%) was performed after 3 months of therapy. The total NIH-CSPI score decreased to 15.6±5.1 (pain score 6.3±3.8, urinary score 4.6±2.2, quality of life 4.7±2), Qmax was 16±3.8 ml/s and mean prostate volume was 24±6 cc. The normalization of laboratory parameters was achieved in all cases.
Conclusion: using the UPOINT classification allows to optimize the treatment of patients with chronic prostatitis. Use of prostate-specific cytomedins (Vitaprost®) is highly effective in case of prostatic involvement according to the UPOINT classification.
About the Autors
Corresponding author: D.V. Ergakov – Ph.D., urologist at the urologic department №2 of GBUZ “City clinical hospital named after D.D. Pletnev of the Health Department c. Moscow”, associate professor at the Department of Urology and Andrology of A.I. Burnazyan SRC FMBC, FMBA of Russia, Moscow, Russia; e-mail: dergakov@mail.ru
Similar Articles
